respiratori
tract
infect
rti
communityacquir
pneumonia
cap
tuberculosi
tb
import
caus
morbid
mortal
ongo
outbreak
middl
east
respiratori
syndrom
coronaviru
merscov
infect
epidem
wave
avian
influenza
sinc
emerg
respect
rais
global
concern
recent
year
huge
clinic
burden
common
respiratori
virus
respiratori
syncyti
viru
rsv
season
influenza
healthcar
resourc
util
highlight
import
develop
effect
treatment
modal
order
reduc
morbid
mortal
contemporari
concis
review
articl
relat
common
respiratori
infect
tb
publish
recent
respirolog
select
articl
publish
journal
highlight
advanc
knowledg
summar
pneumonia
rsv
import
caus
acut
rti
earli
life
high
bacteri
load
colon
upper
rt
often
observ
rsv
infect
children
brealey
et
al
identifi
associ
codetect
rsv
streptococcu
pneumonia
sever
diseas
brisbanebas
cohort
young
children
age
year
acut
rti
suggest
bacteria
may
play
pathogen
role
young
children
find
may
potenti
major
implic
manag
young
children
acut
rti
determin
whether
hospit
requir
direct
appropri
use
antibiot
addit
understand
factor
involv
develop
asthma
new
pathway
immunomodul
tropic
countri
spectrum
pathogen
pneumonia
includ
diseas
melioidosi
scrub
typhu
leptospirosi
hanta
viru
chikungunya
dengu
parasit
pneumonia
patient
hospit
cap
develop
cardiovascular
complic
clinic
mechanist
studi
requir
defin
role
vascular
endotheli
growth
factor
vegf
marker
resolut
lung
inflamm
ventilatorassoci
pneumonia
vap
provis
procalcitonin
assay
result
emerg
depart
hospitalbas
clinician
result
less
use
antibiot
usual
care
among
patient
suspect
lower
rti
macrolid
combin
reduc
mortal
compar
alon
patient
low
drugresist
pathogen
drp
risk
system
corticosteroid
therapi
associ
delay
merscov
rna
clearanc
critic
ill
patient
earli
treatment
patient
avian
influenza
within
day
ill
onset
neuraminidas
inhibitor
nai
reduc
mortal
baloxavir
marboxil
select
inhibitor
influenza
viru
capdepend
endonucleas
effect
treatment
uncompl
influenza
role
adjunct
immunomodul
agent
patient
sever
influenza
deserv
investig
complex
interact
climat
chang
socioeconom
factor
human
migrat
pattern
led
chang
pattern
respiratori
infect
tropic
climat
also
increasingli
temper
countri
tropic
poorer
countri
especi
south
east
asia
account
almost
onethird
global
burden
tb
pandem
addit
tb
lim
siow
emphas
tropic
countri
spectrum
pathogen
pneumonia
includ
diseas
melioidosi
scrub
typhu
leptospirosi
hanta
viru
chikungunya
dengu
parasit
pneumonia
clinician
must
awar
possibl
aetiolog
pneumonia
local
practic
sole
depend
publish
treatment
guidelin
patient
hospit
cap
develop
cardiovascular
complic
new
onset
worsen
cardiac
failur
arrhythmia
myocardi
infarct
cerebrovascular
accid
acut
phase
even
year
thereaft
cardiac
complic
result
complex
interact
comorbid
condit
upregul
sympathet
system
rel
ischaemia
system
inflamm
direct
pathogenmedi
damag
cardiovascular
system
mechan
could
provid
target
futur
therapeut
intervent
reduc
incid
cardiovascular
complic
improv
outcom
patient
cap
signific
increas
human
blood
vegfa
associ
earli
resolut
vap
vegfa
independ
predictor
resolut
despit
diseas
sever
experiment
chronic
pulmonari
infect
pseudomona
aeruginosa
mice
model
led
increas
vegfa
concentr
lung
yet
reciproc
reduct
proinflammatori
cytokin
myeloperoxidas
activ
clinic
mechanist
studi
requir
defin
role
vegfa
marker
resolut
lung
inflamm
vap
standard
approach
treatment
make
cap
target
compar
perform
outcom
measur
hadfield
bennet
discuss
clinicaland
patientreport
outcom
includ
endpoint
time
clinic
stabil
patient
satisfact
strategi
improv
outcom
includ
use
risk
stratif
tool
local
antimicrobi
guidelin
antibiot
stewardship
care
bundl
includ
earli
administr
antibiot
earli
mobil
interestingli
provis
procalcitonin
assay
result
emerg
depart
hospitalbas
clinician
result
less
use
antibiot
usual
care
among
patient
suspect
lower
rti
random
control
trial
rct
involv
hospit
site
usa
limit
publish
data
evalu
effect
antibiot
cap
accord
drp
risk
post
hoc
analysi
prospect
multicentr
cohort
patient
cap
okumura
et
al
shown
macrolid
combin
reduc
mortal
adjust
odd
ratio
ci
compar
alon
addit
among
patient
low
risk
capdrp
independ
host
factor
associ
mortal
includ
high
arteri
carbon
dioxid
paco
level
nonambulatori
statu
leucopenia
low
haematocrit
older
age
tachypnoea
low
serum
albumin
level
low
bodi
temperatur
factor
evalu
futur
clinic
trial
patient
low
capdrp
risk
stratif
assess
antibiot
effect
accompani
editori
water
emphas
import
start
macrolid
earli
follow
short
time
later
thirdgener
cephalosporin
prefer
within
h
present
hospit
saudi
arabia
fig
nosocomi
outbreak
major
hallmark
merscov
infect
largest
outbreak
outsid
middl
east
occur
south
korea
follow
return
businessman
seoul
trip
qatar
uae
saudi
arabia
bahrain
result
total
confirm
case
death
risk
factor
primari
household
nosocomi
transmiss
list
tabl
anoth
businessman
return
seoul
kuwait
august
atyp
present
merscov
infect
includ
diarrhoea
weak
without
respiratori
symptom
improv
infect
control
awar
diseas
surveil
major
outbreak
patient
isol
health
author
quickli
without
caus
outbreak
treatment
merscov
infect
mainli
support
present
rct
progress
saudi
arabia
compar
lopinavirritonavir
mg
bd
day
recombin
subcutan
sc
inject
altern
day
day
standard
support
care
versu
placebo
standard
support
care
patient
laboratoryconfirm
mer
requir
hospit
admiss
difficult
forecast
time
size
sever
influenza
season
despit
advanc
surveil
system
nai
mainstay
treatment
season
avian
influenza
effect
limit
delay
patient
present
manag
earli
treatment
patient
avian
influenza
zhejiang
china
within
day
ill
onset
nai
reduc
mortal
patient
patient
receiv
nai
within
day
die
versu
patient
receiv
treatment
within
day
versu
patient
treat
day
p
median
durat
viral
shed
nai
therapi
initi
day
interquartil
rang
iqr
day
patient
took
nai
within
day
significantli
shorter
took
nai
within
day
day
iqr
day
day
day
iqr
day
p
introduct
bival
vaccin
poultri
mainland
china
octob
result
better
control
outbreak
detect
three
human
case
octob
septemb
correspond
reduct
virus
detect
poultri
environment
sampl
china
baloxavir
marboxil
select
inhibitor
influenza
viru
capdepend
endonucleas
therapeut
activ
preclin
model
influenza
b
viru
infect
includ
strain
resist
current
antivir
agent
earli
treatment
singledos
baloxavir
superior
placebo
allevi
influenza
symptom
patient
year
age
median
differ
h
among
year
age
median
differ
h
addit
baloxavir
superior
oseltamivir
placebo
reduc
viral
load
day
initi
treatment
patient
age
year
uncompl
influenza
although
signific
differ
median
time
allevi
symptom
baloxavir
oseltamivir
recipi
howev
emerg
mutant
virus
develop
decreas
suscept
baloxavir
treatment
small
percentag
case
therapeut
role
baloxavir
older
immunocompromis
patient
sever
season
avian
influenza
especi
time
delay
administr
drug
later
clinic
cours
infect
combin
nai
requir
investig
lee
et
al
found
signific
antiinflammatori
effect
adjunct
macrolid
treatment
adult
sever
influenza
infect
although
viru
rna
declin
unaffect
role
adjunct
immunomodul
agent
patient
sever
influenza
deserv
investig
accord
estim
world
health
organ
million
incid
tb
case
million
tb
death
occur
estim
tb
incid
declin
bare
higher
annual
declin
tb
mortal
unit
kingdom
avail
effect
treatment
social
inequ
continu
hamper
tb
control
mani
part
world
major
gap
remain
reach
diagnos
effect
treat
tb
patient
especi
resourcelimit
set
septemb
head
state
govern
meet
unit
nation
gener
assembl
commit
mobil
us
billion
implement
tb
prevent
care
us
billion
research
annual
basi
hope
import
polit
commit
addit
fund
support
promot
univers
health
coverag
social
protect
facilit
access
qualiti
tb
care
acceler
develop
better
tool
meet
target
end
tb
strategi
unlik
bacteri
infect
singl
critic
concentr
inhibit
growth
phenotyp
wild
type
strain
use
classifi
phenotyp
suscept
resist
tb
drug
howev
may
reflect
achiev
serum
drug
level
clinic
respons
mutant
strain
clinic
breakpoint
minim
inhibitori
concentr
relev
strain
like
respond
treatment
may
inform
isoniazid
rifampicin
fluoroquinolon
drug
use
higher
dose
target
drug
coverag
commerci
rapid
molecular
test
suitabl
direct
applic
clinic
specimen
still
limit
guid
formul
individu
treatment
regimen
mdrrifampicinresist
rr
tb
wholegenom
sequenc
hold
promis
revolution
predict
power
genotyp
drug
suscept
test
cost
throughput
facil
requir
background
nois
replic
error
import
hurdl
overcom
direct
applic
clinic
specimen
bacillari
resist
tb
drug
continu
emerg
new
tb
case
previous
treat
case
mdrrrtb
mdrtb
case
extens
drugresist
xdr
tb
standard
treatment
regimen
facilit
programmat
implement
could
inadvert
acceler
develop
mdrtb
xdrtb
progress
select
resist
mutant
standard
shorter
mdrtb
regimen
show
margin
less
favour
outcom
vs
convent
regimen
preliminari
result
stream
stage
trial
mdrtb
hotspot
eastern
europ
south
east
asia
pakistan
brazil
high
preval
resist
one
drug
use
shorter
regimen
may
render
mdrtb
patient
inelig
regimen
strict
drug
suscept
criteria
partli
base
updat
metaanalysi
observ
data
treatment
mdrtb
world
health
organ
propos
reclassif
tb
drug
use
longer
convent
regimen
mdrtb
three
differ
categori
august
group
drug
includ
levofloxacinmoxifloxacin
bedaquilin
linezolid
priorit
group
b
drug
includ
clofazimin
cycloserineterizidon
ad
next
group
c
drug
ethambutol
delamanid
pyrazinamid
imipenemcilastatin
meropenem
amikacinstreptomycin
ethionamideprothionamid
paminosalicyl
acid
includ
drug
group
b
use
favour
outcom
achiev
optim
background
regimen
treatment
mdrtb
stream
stage
trial
delamanid
trial
need
rel
toxic
drug
linezolid
expens
new
drug
bedaquilin
short
incomplet
establish
safeti
record
remain
establish
least
fluoroquinolonesuscept
mdrtb
age
comorbid
yew
et
al
review
epidemiolog
clinic
mechanist
perspect
tb
older
peopl
highlight
increas
clinic
public
health
challeng
pose
tb
age
popul
mani
asian
countri
complex
interact
among
oxid
stress
mitochondri
dysfunct
immunolog
dysfunct
may
contribut
develop
tb
geriatr
popul
worsen
diseas
outcom
especi
presenc
comorbid
condit
smoke
diabet
mellitu
propens
scorematch
analysi
data
longitudin
health
insur
databas
taiwan
lin
et
al
show
reduct
tb
risk
among
diabet
patient
put
metformin
compar
nonmetformin
user
adjust
comorbid
diabet
complic
antidiabet
therapi
type
statin
use
anoth
longitudin
studi
local
metformin
user
associ
reduct
mortal
tb
treatment
despit
higher
haemoglobin
level
protect
effect
metformin
therefor
appear
independ
diabet
control
sizeabl
protect
effect
metformin
abovement
studi
suggest
potenti
role
drug
hostdirect
therapi
treatment
latent
tb
infect
activ
tb
random
trial
need
delin
exact
role
introduct
clinic
practic
park
et
al
retrospect
review
data
patient
chronic
obstruct
pulmonari
diseas
copd
korean
copd
subtyp
studi
cohort
copd
assess
test
cat
score
total
st
georg
respiratori
questionnair
copd
sgrqc
score
exacerb
preval
significantli
higher
lung
function
significantli
poorer
copd
patient
prior
tb
without
baselin
followup
year
poorer
lung
function
observ
among
patient
prior
tb
irrespect
whether
visibl
lung
lesion
chest
radiograph
despit
introduct
igra
use
specif
antigen
avoid
interfer
prior
bcg
bacillu
calmetteguerin
vaccin
exist
test
latent
tb
infect
predict
biomark
futur
diseas
develop
subject
gener
limit
impos
posit
predict
valu
gener
low
absolut
diseas
risk
shorter
rifamycinbas
regimen
eg
weekli
rifapentin
plu
isoniazid
week
daili
rifampicin
month
prove
safe
effect
altern
month
isoniazid
especi
term
lower
risk
hepatotox
howev
risk
advers
effect
eg
system
hypersensit
reaction
rifamycin
remain
consider
rel
number
tb
case
avert
target
approach
therefor
necessari
optim
benefit
versu
risk
ratio
expens
reduc
popul
coverag
despit
higher
risk
tb
infect
among
household
contact
household
transmiss
account
small
portion
overal
transmiss
ongo
tb
epidem
safeti
rifapentin
pregnanc
remain
establish
even
though
excess
risk
foetal
loss
congenit
anomali
observ
among
pregnant
women
inadvert
expos
either
isoniazid
isoniazid
plu
rifapentin
two
clinic
trial
novel
tb
vaccin
candid
develop
includ
wholecel
vaccin
adjuv
protein
subunit
vaccin
viral
vectordeliv
subunit
vaccin
plasmid
dna
vaccin
rnabas
vaccin
etc
vaccin
use
firstlin
tool
control
infecti
diseas
readili
appli
popul
scale
unlik
prevent
treatment
protect
effect
vaccin
nullifi
reinfect
intervent
howev
high
global
burden
latent
tb
infect
vaccin
capabl
prevent
pulmonari
tb
infect
individu
need
reduc
tb
incid
quickli
least
novel
tb
vaccin
candid
clinic
trial
subunit
vaccin
show
protect
activ
pulmonari
tb
hivneg
adult
posit
igra
recent
phase
iib
trial
proofofconcept
studi
bring
fresh
hope
new
possibl
transform
tb
vaccin
near
futur
